SERUM CYSTATIN C – A NEW MARKER OF GLOMERULAR FILTRATION RATE
Abstract
Background. Estimation of the glomerular filtration rate is an essential part of the evaluation of patients with renal disease. A standard for glomerular filtration rate assessment is CrEDTA clearance. Serum creatinine is the most commonly used marker to estimate the glomerular filtration rate, but it is often not enough accurate. Recently serum cystatin C has been proposed as a new endogenous marker of glomerular filtration rate.
Patients and methods. A total of 231 patients (100 woman and 131 men), who performed CrEDTA clearance in previous 17 months, were enrolled in our study. In each patient serum creatinine and serum cystatin C were also determined. Average age of our patients was 55 years (from 7 to 85 years).
Results. Average CrEDTA clearance was 54.4 ml/min/1.73 m2 (from 2 to 186 ml/min/1.73 m2). Average serum creatinine concentration was 270.2 µmol/l (from 64 to 915 µmol/l) and average serum cystatin C concentration was 2.53 mg/l (from 0.59 to 6.99 mg/l). The correlations between CrEDTA clearance, serum creatinine and serum cystatin C were statistically significant. The correlation between CrEDTA clearance and serum cystatin C was better than correlation between CrEDTA clearance and serum creatinine.
Conclusions. CrEDTA clearance, serum creatinine and serum cystatin C are comparable markers of renal function. Based on our study, serum cystatin C is a more reliable measure of glomerular filtration rate than serum creatinine.
Downloads
References
Burton D, Theodore W. Up to date. 2001; Vol. 9 on CD-ROM.
Heymsfield SB, Arteaga C, Maccanus C, Smith J, Moffitt S. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr 1983; 37: 478–94.
Coresh J, Toto RD, Kirk KA et al. Creatinine clearance as a measure of GFR in screenees for the African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis 1998; 32: 32–42.
Clausen J. Proteins in normal cerebrospinal fluid not found in serum. Proc Soc Exp Biol Med 1961; 107: 170–2.
Butler EA, Flynn FV. The occurence of part gamma protein in urine: a new protein abnormality. J Clin Path 1961; 14: 172–8.
Cameron JS, Greger R. Renal function and testing of function. In: Davison AM, Cameron S, Grunfeld JP, Kerr DNS, Ritz E, Winearls CG eds. Oxford textbook of clinical nephrology. 2nd edition. Vol. 1. Oxford, New York, Tokyo: Oxford University Press, 1998: 39–69.
Levey AS, Berg RL, Gassmann JJ, Hall PM, Walker WG. Creatinine filtration, secretion and excretion during progressive renal disease. Kidney Int 1989; 36: Suppl 27: S73–80.
Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38: 1933–53.
Doolan PD, Alpen EL, Theil GB. A clinical apppraisal of the plasma concentration and endogenous clearance of creatinine. Am J Med 1962; 32: 65–79.
Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830–8.
Kim KE, Onesti G, Ramirez O et al. Creatinine clearance in renal disease. A reappraisal. Br Med J 1969; 4: 11–4.
Bauer JH, Brooks CS, Burch RN. Clinical appraisal of creatinine clearance as a measurement of glomerular filtration rate. Am J Kidney Dis 1982; 2: 337– 46.
Levey AS. Measurement of renal function in chronic renal disease. Kidney Int 1990; 38: 167–84.
Randers E, Erlanndsen EJ. Serum cystatin C as an endogenous marker of the renal function: a review. Clin Chem Lab Med 1999; 37: 389–95.
Deinum J, Derkx FHM. Cystatin for estimation of glomerular filtration rate? Lancet 2000; 356: 1624–5.
Kos J, Štabuc B, Cimerman N, Brünner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 1998; 44: 2556–7.
Štabuc B, Vrhovec L, Štabuc-Šilih M, Cizej TE. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 2000; 46: 193–7.
Finney H, Williams AH, Price CP. Serum cystatin C in patients with myeloma. Clin Chim Acta 2001; 309: 1–6.
Filler G, Witt I, Priem F, Ehrich JHH, Jung K. Are cystatin and beta microglobulin better markers than serum creatinine for prediction of a normal glomerular filtration rate in pediatric subjects? Clin Chem 1997; 43: 1077–8.
Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C – a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998; 101: 875–81.
Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as amarker of kidney function: a meta analysis. Am J Kidney Dis 2002; 40: 221–6.
Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001; 37: 79–83.
Nitta K, Hayashi T, Uchida K et al. Serum cystatin C as a marker of glomerular filtration rate in patients with various renal disease. Intern Med 2002; 41: 931–5.
Tamba K, Kusano E, Ando Y, Asano Y. Prospective evaluation of renal function testing by serum cystatin C: comparison with three other parameters of glomerular filtration rate. Nippon Jinzo Gakkai Shi 2001; 43: 646–50.
Kazama JJ, Kutsuwada K, Ataka K, Maruyama H, Gejyo F. Serum cystatin C reliably detects renal disfunction in patients with varios renal disease. Nephron 2002; 91: 13–20.
Thomassen SA, Johannesen IL, Erlandsen EJ, Abrahamsen J, Randers E. Serum cystatin C as a marker of the renal function in patients with spinal cord injury. Spinal Cord 2002; 40: 524–8.
Poge U, Stoschus B, Stofel-Wagner B et al. Cystatin C as an endogenous marker of glomerular filtration rate in renal transplant patients. Kidney Blood Press Res 2003; 26: 55–60.
Hermida J, Romero R, Tutor JC. Relationship between serum cystatin C and creatinine in kidney and liver transplant patients. Clin Chim Acta 2002; 316: 165–70.
Risch L, Blumberg A, Huber AJ. Assessment of renal function in renal transplant patients using cystatin C. A comparison to other renal function markers and estimates. Ren Fail 2001; 23: 439–48.
Paskalev E, Lambreva L, Simeonov P et al. Serum cystatin C in renal transplant patients. Clin Chim Acta 2001; 310: 53–6.
Demirtas S, Bozbas A, Akbay A, Yavuz Y, Karaca L. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta 2001; 311: 81–9.
Mussap M, Dalla Vestra M, Fioretto P et al. Cystatin C is more sensitive marker than creatinine for the estimation of glomerular filtration in type 2 diabetic patients. Kidney Int 2002; 61: 1453–61.
Jovanović D, Krstivojević P, Obradović I, Durdević V, Dukanović L. Serum cystatin and β2 microglobulin as markers of glomerular filtration rate. Ren Fail 2003; 25: 123–33.
Donadio C, Lucchesi A, Ardini M, Giordani R. Cystatin C, β2 microglobulin, andretinol binding proteins as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biom Anal 2001; 24: 835–42.
Oddoze C, Morange S, Portugal H, Berland Y, Dussol B. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis 2001; 38: 310–6.
Shuck O, Teplan V, Jabor A, Stollova M, Skibova J. Glomerular filtration rate estimation in patients with advanced chronic renal insufficiency based on serum cystatin C levels. Nephron Clin Pract 2003; 93: 146–51.
Burkhardt H, Bojarsky G, Gladisch R. Diagnostic efficiency of cystatin C and serum creatinine as markers of reduced glomerul filtration rate in the elderly. Clin Chem Lab Med 2002; 40: 1135–8.
Van Den Noortgate NJ, Janssens WH, Delanghe JR, Afschrift MB, Lameire NH. Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old old. J Am Geriatr Soc 2002; 50: 1278–82.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
